Our bioluminescent light-producing oncology cell lines are labeled with luciferase or dual labeled with luciferase and fluorescent reporters (GFP) for in vivo studies.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
You successfully added item(s) to your cart
The HT29-Red-FLuc Bioware® Brite Cell Line is a light-producing cell line derived from HT29-human colorectal adenocarcinoma. The cells have been stably transduced with the red-shifted firefly luciferase gene from Luciola Italica (Red-FLuc), for a brighter, red-shifted signal.
This cell line has very bright bioluminescence, emitting at least 30,000 photons/cell/sec in vitro. The exact number will vary depending on imaging and culturing conditions.
By emitting intensified, longer wavelength light that is significantly brighter than other firefly luciferases, our bioluminescent oncology cell lines allow you to visualize and monitor the growth of deep tissue tumors in vivo.
After the cells are injected into an appropriate mouse model, the optimized Red-FLuc luciferase enables more sensitive in vivo optical detection with less tissue attenuation so you can detect tumor development earlier.
Disclaimer: For laboratory use only. This product is intended for animal research only and not for use in humans.
|Oncology Cell Line||Colorectal|
|Product Brand Name||Bioware Brite|
|Quantity in a Package Amount||1.0 Units|
|Shipping Condition||Dry Ice|
|Unit Size||2 million cells|
You have selected:
|Resource Type||File Name||File Format|
|Brochure||In Vivo Imaging Agents Brochure||PDF 2 MB|
|Guide||Bioware Brite Cell Culture Guidelines||PDF 310 KB|
|Guide||Cell Preparation and Instructions for In Vivo Injection of Bioware® CellsBrite Tumor Cells||PDF 169 KB|
|Poster (All)||Fluorescence tomographic imaging of efficacy & toxicity following acute 5-FU treatment of HT29 cells||PDF 2 MB|
|Citations Library||View peer reviewed publications using PerkinElmer's In Vivo Imaging Reagents||Link|
|Webinars||View our complete list of in vivo webinars available on demand||Link|